Literature DB >> 18053021

The socio-economic burden of asthma is substantial in Europe.

S Accordini1, A Corsico, I Cerveri, D Gislason, A Gulsvik, C Janson, D Jarvis, A Marcon, I Pin, P Vermeire, E Almar, M Bugiani, L Cazzoletti, E Duran-Tauleria, R Jõgi, A Marinoni, J Martínez-Moratalla, B Leynaert, R de Marco.   

Abstract

BACKGROUND: Few data are available on the asthma burden in the general population. We evaluated the level and the factors associated with the asthma burden in Europe.
METHODS: In 1999-2002, 1152 adult asthmatics were identified in the European Community Respiratory Health Survey (ECRHS)-II and the socio-economic burden (reduced activity days and hospital services utilization in the past 12 months) was assessed.
RESULTS: The asthmatics with a light burden (only a few reduced activity days) were 13.2% (95% CI: 11.4-15.3%), whereas those with a heavy burden (many reduced activity days and/or hospital services utilization) were 14.0% (95% CI: 12.1-16.1%). The burden was strongly associated with disease severity and a lower quality of life. Obese asthmatics had a significantly increased risk of a light [relative risk ratio (RRR) = 2.17; 95% CI: 1.18-4.00] or a heavy burden (RRR = 2.77; 95% CI: 1.52-5.05) compared with normal/underweight subjects. The asthmatics with frequent respiratory symptoms showed a threefold (RRR = 2.74; 95% CI: 1.63-4.61) and sixfold (RRR = 5.76; 95% CI: 3.25-10.20) increased risk of a light or a heavy burden compared with asymptomatic asthmatics, respectively. Moreover, the lower the forced expiratory volume in 1 s % predicted, the higher the risk of a heavy burden. The coexistence with chronic cough/phlegm only increased the risk of a heavy burden (RRR = 1.88; 95% CI: 1.16-3.06). An interaction was found between gender and IgE sensitization, with nonatopic asthmatic females showing the highest risk of a heavy burden (21.6%; 95% CI: 16.9-27.1%).
CONCLUSIONS: The asthma burden is substantial in Europe. A heavy burden is more common in asthmatics with obesity, frequent respiratory symptoms, low lung function, chronic cough/phlegm and in nonatopic females.

Entities:  

Mesh:

Year:  2008        PMID: 18053021     DOI: 10.1111/j.1398-9995.2007.01523.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  29 in total

1.  Pharmacoepidemiological Study of Long-Acting β-agonist/Inhaled Corticosteroid Therapy and Asthma Mortality: Clinical Implications.

Authors:  Carlos A Camargo; Kourtney J Davis; Elizabeth B Andrews; David A Stempel; Michael Schatz
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

2.  Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids.

Authors:  Eric D Bateman; Alfredo G Guerreros; Florian Brockhaus; Björn Holzhauer; Abhijit Pethe; Richard A Kay; Robert G Townley
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

3.  Skin prick test reactivity to common aeroallergens and ARIA classification of allergic rhinitis in patients of Central Greece.

Authors:  K K Anastassakis; A Chatzimichail; I Androulakis; S Charisoulis; Maria Riga; Anna Eleftheriadou; V Danielides
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01       Impact factor: 2.503

Review 4.  Small airway dysfunction and poor asthma control: a dangerous liaison.

Authors:  Marcello Cottini; Anita Licini; Carlo Lombardi; Diego Bagnasco; Pasquale Comberiati; Alvise Berti
Journal:  Clin Mol Allergy       Date:  2021-05-29

5.  Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy.

Authors:  Isabella Ruggeri; Donatello Bragato; Giorgio L Colombo; Emanuela Valla; Sergio Di Matteo
Journal:  Clinicoecon Outcomes Res       Date:  2012-12-05

6.  The impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities: a population-based observational study.

Authors:  Simone Accordini; Angelo Guido Corsico; Lucia Calciano; Roberto Bono; Isa Cerveri; Alessandro Fois; Pietro Pirina; Roberta Tassinari; Giuseppe Verlato; Roberto de Marco
Journal:  BMC Pulm Med       Date:  2015-02-12       Impact factor: 3.317

7.  Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.

Authors:  Giorgio Walter Canonica; Giorgio Lorenzo Colombo; Paola Rogliani; Pierachille Santus; Claudia Pitotti; Sergio Di Matteo; Chiara Martinotti; Giacomo Matteo Bruno
Journal:  Risk Manag Healthc Policy       Date:  2020-01-22

8.  EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

Authors:  Moises A Calderon; Pascal Demoly; Roy Gerth van Wijk; Jean Bousquet; Aziz Sheikh; Anthony Frew; Glenis Scadding; Claus Bachert; Hans J Malling; Rudolph Valenta; Beatrice Bilo; Antonio Nieto; Cezmi Akdis; Jocelyne Just; Carmen Vidal; Eva M Varga; Emilio Alvarez-Cuesta; Barbara Bohle; Albrecht Bufe; Walter G Canonica; Victoria Cardona; Ronald Dahl; Alain Didier; Stephen R Durham; Peter Eng; Montserrat Fernandez-Rivas; Lars Jacobsen; Marek Jutel; Jörg Kleine-Tebbe; Ludger Klimek; Jan Lötvall; Carmen Moreno; Ralph Mosges; Antonella Muraro; Bodo Niggemann; Giovanni Pajno; Giovanni Passalacqua; Oliver Pfaar; Sabina Rak; Gianenrico Senna; Gabriela Senti; Erkka Valovirta; Marianne van Hage; Johannes C Virchow; Ulrich Wahn; Nikolaos Papadopoulos
Journal:  Clin Transl Allergy       Date:  2012-10-30       Impact factor: 5.871

9.  Diverging trends of chronic bronchitis and smoking habits between 1998 and 2010.

Authors:  Simone Accordini; Angelo Guido Corsico; Isa Cerveri; Leonardo Antonicelli; Francesco Attena; Roberto Bono; Lucio Casali; Marcello Ferrari; Alessandro Fois; Pierpaolo Marchetti; Pietro Pirina; Roberta Tassinari; Giuseppe Verlato; Roberto de Marco
Journal:  Respir Res       Date:  2013-02-08

10.  Single nucleotide polymorphisms predisposing to asthma in children of Mauritian Indian and Chinese Han ethnicity.

Authors:  K Ramphul; J Lv; L Hua; Q H Liu; D Z Fang; R X Ji; Y X Bao
Journal:  Braz J Med Biol Res       Date:  2014-05       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.